Biotechnology Sector Soars: Strategic Partnerships and Regulatory Wins Drive Top Stock Gains

Font: Financial Modeling Prep  • Jun 24, 2026

• Biotechnology companies experienced significant gains driven by specific positive news and key developments.
• Strategic partnerships, such as Pulsenmore's collaboration with Ouma Health, are expanding access to innovative healthcare solutions like remote prenatal care.
• Regulatory approvals (e.g., FDA clearance) and positive clinical trial data are crucial catalysts for strong stock performance and growth in the biotech industry.

Today's market highlights significant gains in the biotechnology sector, with companies showing strong market performance based on key developments. Leading the pack is Pulsenmore (NASDAQ: PLSM), which closed at $6.59, a remarkable 93.26% increase. The stock's trading volume exploded to over 57.8 million shares, far exceeding its average of about 17,835 shares.

The massive investor interest in Pulsenmore is linked to its new strategic partnership with Ouma Health. This collaboration will integrate Pulsenmore's FDA-authorized home ultrasound technology into Ouma Health's virtual maternity care. This move is set to expand remote prenatal care access across the United States, explaining the stock's dramatic surge.

IceCure (NASDAQ: ICCM) also saw a major increase, rising 51.96% to $9.30, with a trading volume of 13.35 million shares. This gain follows a new peer-reviewed article in the International Journal of Surgery. The article presents the clinical advantages of IceCure's ProSense® cryoablation technology for treating early-stage breast cancer.

Similarly, Cuprum (NASDAQ: CUPR) climbed 45.69% to $5.74 after receiving FDA clearance for its MEDIFLY Maggots product for persistent wounds. Other notable movers include Novacyt (NASDAQ: NVCT), which rose 39.49% to $24.48 after licensing two new experimental drugs. Absci (NASDAQ: ABSI) also gained 35.96% to $10.08, following positive Phase 1 results and a $100 million stock offering.

In summary, the day's top gainers demonstrate how positive company-specific news drives market performance. Investors are clearly rewarding tangible progress, such as regulatory approvals, strategic partnerships, and positive clinical data, which are key milestones for growth in the biotechnology industry.